about
Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinomaCirculating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insightsHepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseasesLiverCancerMarkerRIF: a liver cancer biomarker interactive curation system combining text mining and expert annotationsBiobanking for research in surgery: are surgeons in charge for advancing translational research or mere assistants in biomaterial and data preservation?Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapyProtein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populationsEvaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis.Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.Identification of Circulating Biomarker Candidates for Hepatocellular Carcinoma (HCC): An Integrated Prioritization Approach.Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum.HAX-1 is overexpressed in hepatocellular carcinoma and promotes cell proliferationCAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.DNMT3A -448A>G polymorphism and the risk for hepatocellular carcinoma.Aided Diagnosis of Hepatocellular Carcinoma Using Serum Fucosylated Haptoglobin RatiosEvaluation of liver cirrhosis and hepatocellular carcinoma using Protein-Protein Interaction Networks.Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility.Identification of circulating MicroRNAs as novel potential biomarkers for hepatocellular carcinoma detection: a systematic review and meta-analysis.Clinical significance of half-lives of the tumor markers alpha-fetoprotein and des-γ-carboxy prothrombin after hepatectomy for hepatocellular carcinoma.Glucose-regulated protein 94 mediates metastasis by CCT8 and the JNK pathway in hepatocellular carcinoma.Glucose-regulated protein 94 mediates cancer progression via AKT and eNOS in hepatocellular carcinoma.High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma.Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma.Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma.In vivo antitumour potential of camel's milk against hepatocellular carcinoma in rats and its improvement of cisplatin renal side effects.HCC-DETECT: a combination of nuclear, cytoplasmic, and oncofetal proteins as biomarkers for hepatocellular carcinoma.Gamma-irradiated β-glucan modulates signaling molecular targets of hepatocellular carcinoma in rats.Plasma HSP90α and liver cancer: a potential biomarker?Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma.Predictors of post-hepatectomy liver failure in patients undergoing extensive liver resections for hepatocellular carcinoma
P2860
Q26740332-BCF57544-3057-40BB-8208-9F17A6214962Q26799928-298164D0-69C5-4234-936C-088B77E07165Q27024630-27E27BCE-B3C9-40AA-BD01-8D8B2014B00EQ28656408-B57810F9-6540-4349-B856-26C25E55A369Q30592366-80D09033-DF01-46AF-B303-4151B502A685Q34028475-6997C8FE-F123-4A80-A29F-E2E8152A4BF3Q34256150-1192C0F5-EB21-4528-A0F7-DCF5FA380A5DQ34918154-37E63A5B-3DFC-4C33-9A15-8562DD55B27CQ35062428-D1A871F4-E363-416B-BBD0-F26AA64B828EQ35626761-DA9F9F64-F6B7-40BB-B213-4301B1685545Q35790450-FB5EC667-8D1B-494D-8727-CDD8658AB421Q35832909-A1A4F8AD-3300-470B-89FC-CF6ED9E01963Q36014285-D5B8B0B9-00B3-4074-BAB6-8C5D7ECE8F73Q37559401-55F57512-10A4-457E-9B04-2AFAEEAD5215Q37565613-13FBBBF9-735F-43AB-8923-886DAA764993Q37738102-0EEA667D-23EB-4E08-B966-A2756226CBAAQ38436698-5614D472-187D-4D34-AD9A-73F26733DDD6Q38450711-73B84EA0-3C5E-416E-AD75-4B04AA6FB6F4Q38468383-BC697AF0-8EEE-4628-B33E-82D7CA1C10ACQ38630633-FF924CAF-D70E-4E3C-AD49-4C416458358BQ38807896-AD52B402-2488-4D0B-A15F-C499DF4BBF09Q38825761-93EE4E87-7110-42D2-BAA7-32B2D1724321Q40917751-EB6A5DD7-13ED-4259-A750-6B43062EBAA7Q41460733-85B40627-3558-4DAD-8D1C-3279F0C5E41BQ42366620-094DDA9A-5CB1-4670-98EF-4474492B6CCCQ43544108-F7C5A8D0-2E0C-41E8-8B8C-800C7EEA06EBQ46391250-E97266CB-E8F2-4753-A280-399DB515FFBAQ46397764-591FBDE5-3675-4853-8AD3-C640E036F18CQ46659792-1666DBB6-D217-46E4-BDCA-5099400D77C5Q47108351-FFF8D268-8C3C-4D58-8C8F-65D6C8B723BFQ47738876-D5858817-0EFF-431F-9C58-A67A2825191DQ58781332-C7DAEF17-2108-4E63-AAF9-BF395917CB2A
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Biomarkers for hepatocellular carcinoma
@ast
Biomarkers for hepatocellular carcinoma
@en
Biomarkers for hepatocellular carcinoma
@en-gb
Biomarkers for hepatocellular carcinoma
@nl
type
label
Biomarkers for hepatocellular carcinoma
@ast
Biomarkers for hepatocellular carcinoma
@en
Biomarkers for hepatocellular carcinoma
@en-gb
Biomarkers for hepatocellular carcinoma
@nl
altLabel
Biomarkers for Hepatocellular Carcinoma
@en
prefLabel
Biomarkers for hepatocellular carcinoma
@ast
Biomarkers for hepatocellular carcinoma
@en
Biomarkers for hepatocellular carcinoma
@en-gb
Biomarkers for hepatocellular carcinoma
@nl
P2860
P356
P1476
Biomarkers for hepatocellular carcinoma
@en
P2093
M Sitki Copur
Tara Behne
P2860
P304
P356
10.1155/2012/859076
P407
P577
2012-01-01T00:00:00Z